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Abstract
Objective—To investigate the relationship between abdominal ultrasound (US) findings and 
demographic, historical and clinical features in children with CF.
Study design—Children age 3-12 years with CF without known cirrhosis, were enrolled in a 
prospective, multi-center study of US to predict hepatic fibrosis. Consensus US patterns were 
assigned by 3 radiologists as normal, heterogeneous, homogeneous, or cirrhosis. Data were 
derived from direct collection and U.S. or Toronto CF registries. Chi-square or ANOVA were 
used to compare variables among US groups and between normal and abnormal. Logistic 
regression was used to study risk factors for having abnormal US.
Results—Findings in 719 subjects were normal (n=590, 82.1%), heterogeneous (64, 8.9%), 
homogeneous (41, 5.7%), and cirrhosis (24, 3.3%). Cirrhosis (p=0.0004), homogeneous 
(p<0.0001) and heterogeneous (p=0.03) were older than normal. More males were heterogeneous 
(p=0.001). More heterogeneous (15.0%, p=0.009) and cirrhosis (25.0%, p=0.005) had CF-related 
diabetes or impaired glucose tolerance versus normal (5.4%). Early infection with Pseudomonas 
aeruginosa (<2 years old) was associated with a lower risk (OR 0.42, p=0.0007) of abnormal. 
Ursodeoxycholic acid use (OR 3.69, p <0.0001) and CF-related diabetes (OR 2.21, p=0.019) were 
associated with increased risk of abnormal.
Conclusions—Unsuspected cirrhosis is seen in 3.3% of young patients with CF, heterogeneous 
in 8.9%. abnormal US is associated with CF-related diabetes, and early P aeruginosa is associated 
with normal US. Prospective assessment of these risk factors may identify potential interventional 
targets.
Keywords
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There are significant limitations in the identification and classification of liver disease in 
patients with CF 1,2. This gap primarily reflects a lack of reliable, sensitive, and specific 
diagnostic markers of liver involvement in CF prior to the development of clinically evident 
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cirrhosis with portal hypertension. A mild degree of liver involvement is common among 
patients with CF, but most natural history studies suggest a prevalence of multilobular 
cirrhosis in CF of between 5 and 15%. Virtually all cases are identified before 20 years of 
age,3-5 indicating that advanced liver disease in CF is a disorder of children.
A heterogeneous echogenicity pattern of the liver on abdominal ultrasound (US) has been 
suggested to identify patients with CF at increased risk for cirrhosis 6. Between 9 and 25% 
of children with CF are reported to have a heterogeneous pattern on US 6-8. In a single 
center study, 67% of patients with a heterogeneous pattern on US progressed to features 
consistent with cirrhosis and 46% of these progressed to portal hypertension with an average 
follow-up of 10 years6. In patients with a normal echogenicity pattern on US, only 7-13% 
developed US findings of cirrhosis and 5-7.5% progressed to portal hypertension 6. Thus, 
patients with a heterogeneous pattern of the liver on US demonstrated a 5.2 fold increased 
incidence of cirrhosis and a 6.1 fold increased incidence of portal hypertension compared 
with children with a normal echogenicity pattern.
In prior studies, sample size has limited the ability to investigate potential correlations 
between demographic, historic or clinical factors and US findings. We hypothesized that 
there would be demographic and clinical features associated with each US pattern. 
Specifically, we sought to determine if early or current nutritional status, early infections, 
antibiotic use and access to care were associated with abnormal baseline US.
Methods
The Cystic Fibrosis Liver Disease Network (CFLD-NET) is a North American multicenter 
group conducting a prospective study investigating the utility of abdominal US to identify 
young children at risk for the development of cirrhosis (Prediction by Ultrasound of the Risk 
of Hepatic Cirrhosis in Cystic Fibrosis [PUSH]; ClinicalTrials.gov: NCT01144507). Official 
registration for this trial was delayed due to administrative issues requiring clarification by 
the multiple sponsors. As such, 146 of the 722 subjects (20%) reported in this study were 
enrolled prior to the registration approval date of June 14, 2010. However, no data were 
examined, and no interval analysis was conducted prior to registration. The protocol was 
reviewed and approved by the Institutional Review Boards at all participating centers. Study 
subjects were recruited from 11 CF centers within the network. All guardians provided 
informed consent and appropriate assent was obtained. Children 3-12 years of age were 
eligible for the study based on the following inclusion criteria: (1) diagnosed with CF as 
determined by a sweat chloride of >60 mEq/L or two disease-causing CFTR genetic 
mutations with evidence of end organ involvement; (2) enrolled in either the United States 
or Toronto CF registry; and (3) diagnosed with pancreatic insufficiency as indicated by one 
of the following: CFTR mutations associated with pancreatic insufficiency, 9 fecal elastase 
<100 micrograms/gm (at any time), or 72 hour fecal fat with coefficient of fat absorption 
<85% (at any time).
Exclusion criteria were: known cirrhosis or portal hypertension (ie, splenomegaly, ascites), 
prior identification of Burkholderia species on respiratory cultures, or short bowel 
syndrome, defined as requiring any parenteral nutrition after 3 months of age.
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Data collected included demographics, CFTR genotype, and abdominal US findings. The 
United States and Toronto CF registries were utilized for historical and clinical data, 
including medical insurance, symptoms at diagnosis, history of malnutrition, infection, lung 
function, complications, and medications. CF-related diabetes or impaired glucose tolerance 
is defined in the registries as 2-hour glucose levels of 140 to 199 mg per dL on the 75-g oral 
glucose tolerance test. US was performed with state-of-the-art equipment with both gray-
scale and Doppler imaging at each site.
Grading followed the system of Williams et al 10. Liver echogenicity and contours were 
assessed to classify a patient into one of four US patterns. Normal denoted that the subject 
had normal hepatic echogenicity. Heterogeneous denoted that the subject had increased 
echogenicity that was diffusely patchy or limited to periportal regions. Homogeneous 
denoted that the subject had diffusely increased hepatic parenchymal echogenicity relative to 
renal echogenicity, absent or poor definition of portal venous and hepatic structures, and 
posterior beam attenuation with absent or incomplete diaphragm visualization. Cirrhosis 
pattern denoted that the subject had a heterogeneous echogenicity and coarse echotexture of 
the liver parenchyma and obvious nodularity of the liver contour.
A single radiologist from each center participating in the PUSH study read all the US studies 
locally. Participating radiologists underwent web based training for the grading of the US 
studies. A training set of representative images from each grade was developed by the lead 
radiologist. Validation of consistency (κ>0.7) in the readings was assessed with the training 
set prior to initiation of the study. In addition, the lead radiologist reviewed the first 5 
ultrasound studies from every site for quality to ensure uniform quality and validated degree 
of concordance before study continuation. The same training set used for the radiologists 
was used to train the sonographers. In addition, there was a written guide documenting the 
required images for the sonographers.
At study entry, each enrolled subject, underwent a standardized abdominal US to include a 
survey examination of the entire abdomen and a detailed examination of the liver and spleen 
to assess for presence or absence of liver disease. The gray-scale images were the 
determinant of those who had longitudinal follow-up. US findings were independently 
graded as normal, heterogeneous, homogeneous or cirrhosis by 3 study radiologists 
randomly assigned from the different participating study sites in regular rotation and blinded 
to the results of the other interpretations. The consensus grade was assigned by majority. In 
rare cases, a 4th reader was invited to grade the ultrasound if there were 3 different grades, as 
a tiebreaker. If 4 different grades were submitted, the patient was excluded from the study.
Statistical analyses
We utilized descriptive statistics to describe demographic and clinical features, and medical 
history of patients in the normal and abnormal groups separately. ANOVA or Kruskal-
Wallis test for continuous variables and Chi-square or Fisher's exact tests for categorical 
variables were used to test difference between the four groups. We then used logistic 
regression to determine risk factors for abnormal US findings (abnormal: heterogeneous, 
homogeneous, or cirrhosis) adjusting for age at US as a covariate. Each risk factor was 
included in the regression model individually. To investigate any potential negative impact 
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that different US grades had on lung function, we used a mixed effects model to test whether 
population mean forced expiratory volume in 1 second (FEV1 % predicted) trajectories 
significantly differed between the four US groups. Because FEV1 measurements are not 
reliably obtained in children under 6 years of age, we only included subjects older than 6 
years of age at the time of screening US in this part of the analysis.
Results
Patients in this study were enrolled from January 21, 2010, to February 7, 2014; 722 
subjects were enrolled and assigned a final US grade, but 719 were eligible and successfully 
matched to the US CF or Toronto registry (three were found to be ineligible after screening 
US). The distribution of the US findings and the demographic features are shown in Table I. 
The majority of subjects had a normal pattern (82.1%) with 8.9% heterogeneous, 5.7% 
homogeneous and 3.3% cirrhosis. Overall, 17.9% were abnormal. The subjects with 
heterogeneous, homogeneous, and cirrhosis patterns were all older than the normal group 
(Table I and Figure; Figure available at www.jpeds.com). Heterogeneous subjects were 
more likely to be male (p=0.0018) and had differences in race distribution when compared 
with the normal group (p=0.02). There were no Hispanic subjects in the heterogeneous 
group compared with 8% of Hispanic in the normal group. More homogeneous patients 
were diagnosed with meconium ileus than normal subjects (p=0.015). There was no 
correlation between genotype and US pattern.
We then investigated the association of current nutritional status with US findings (Table II). 
Homogeneous subjects had a significantly higher BMI age adjusted z-score than normal 
subjects, but only 6/40 (15%) of homogeneous subjects had a BMI z-score of >1.5. More 
heterogeneous (15.0%) and cirrhosis (25.0%) patients were diagnosed with CF-related 
diabetes or impaired glucose tolerance compared with normal (5.4%) subjects. More 
homogeneous patients (11.4%, p=0.03) and patients with cirrhosis (25.0%, p=0.0006) were 
identified in the registry with non-cirrhotic liver disease compared with normal (3.1%) 
subjects.
There were no differences in proportion of Pseudomonas culture positivity between groups 
at the time of US (Table II). We studied the relationship between the change over time in 
pulmonary function as measured by FEV1 and US category for children over 6 years of age 
using a linear mixed effect model. We did not find any significant difference between 
groups in either rate of FEV1 decline (p=0.54) or FEV1 at 6 years of age (p=0.24).
Univariate analysis of potential risk factors for the US finding was performed (Table III). 
Compared with normal, both heterogeneous subjects and those with cirrhosis were less 
likely to be diagnosed with CF before 3 months of age, or to have a Pseudomonas 
aeruginosa infection before 2 years of age and were more likely to have used 
ursodeoxycholic acid at any time in the past (Table III). Subjects with cirrhosis also were 
more likely than normal to have used macrolide antibiotics at any time in the past (Table 
III). Compared with normal, homogeneous subjects were more likely to have had meconium 
ileus and prior reported use of ursodeoxycholic acid (Table III). There were no differences 
among the groups in the early use (before 2 years of age) of medications including 
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antifungals, steroids, acid blockers, oral corticosteroids, ursodeoxycholic acid, or macrolide 
antibiotics or in insurance status (data not shown).
To evaluate the possibility that some of our findings might be confounded by subject age, 
we performed univariate logistic regression analysis to identify risk factors for any abnormal 
US (heterogeneous, cirrhosis or homogeneous) adjusting for age at screening US (Table IV). 
After adjusting for age, early infection with Pseudomonas aeruginosa (<2 years of age) 
(p=0.0007), ursodeoxycholic acid use before US (<0.0001) at any time in the past, and CF-
related diabetes/impaired glucose tolerance (p=0.019) were still significantly associated with 
abnormal. Pseudomonas aeruginosa infection before 2 years of age lowered the odds ratio 
of being in the abnormal group by 60%. Early ursodeoxycholic acid use was associated with 
a 4 fold increase and having CF-related diabetes or impaired glucose tolerance was 
associated with a 2 fold increase in the odds of being in the abnormal group. We performed 
a comparable analysis excluding homogeneous from the abnormal group and found similar 
results.
Discussion
In this prospective study, abnormalities in US patterns are present in 18% of children with 
pancreatic insufficient CF, which is in agreement with data from Patriquin et al obtained >15 
years ago 8. Although the distribution of US abnormalities in our study is similar, the overall 
prevalence of heterogeneous US findings in our cohort is higher than that previously 
reported 7,10. Unexpectedly, an US pattern of cirrhosis was found in 3.3% of subjects who 
had no clinical evidence of liver disease such as portal hypertension (ie, splenomegaly, 
ascites) or thrombocytopenia. This is consistent with prior reports and suggests that cirrhosis 
may present early in life. The possibility of detecting CF cirrhosis in its earliest stages, prior 
to the development of clinical signs or symptoms, has implications for establishing 
important clinical endpoints that could be tracked when therapeutic drugs become available. 
The PUSH study illustrates that sonographic echotexture abnormalities are common in CF 
patients, but their ability to predict clinical outcomes such as the risk for the development of 
cirrhosis, will only be determined through long term follow up. At study entry, a 
heterogeneous pattern was demonstrated in 8.9%, and 5.7% had an homogeneous pattern. It 
is also possible that the US findings will vary over time, with intermittent hepatic injury and 
repair, or due to as yet to be determined factors. Notably, subjects with an abnormal US 
were older and more likely to be male in the heterogeneous group than those with a normal 
pattern. This is consistent with a higher frequency of multilobular cirrhosis in males 11 and 
further suggests that there indeed may be a progression from heterogeneous to cirrhosis.
A homogeneous echogenic pattern is felt to reflect hepatic steatosis 12. In the non-CF 
pediatric population, a homogeneous pattern is most frequently associated with nonalcoholic 
fatty liver disease (NAFLD) related to obesity13. In our subjects, even though there was a 
higher BMI z-score in those with a homogeneous pattern, only 15% of those in the 
homogeneous group were overweight (BMI z score >1.5). Thus, in CF the homogeneous 
pattern is not exclusive to overweight children. CF specific dietary interventions, 
medications, and nutritional deficiencies such as protein-calorie malnutrition or essential 
fatty acid and fat soluble vitamin deficiency may influence the development of the 
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homogeneous pattern. NAFLD disproportionally affects Hispanic persons, so it was not 
surprising that nearly 20% of our homogeneous subjects were Hispanic14,15. However, there 
were no Hispanic subjects in our reported heterogeneous group, despite representation 
among the other US grades. In light of these findings, it is still not clear if homogeneous is 
part of the progression of heterogeneous to cirrhosis. Correlation of homogeneous US 
findings and liver biopsy in patients with CF has not yet been undertaken.
This study allowed us to investigate potential clinical and historical factors associated with 
an abnormal US. Previously suggested factors for liver involvement in CF including 
meconium ileus, undernutrition, and worse FEV1 were not found to be associated with 
abnormal US patterns in our study3,6,7. The age-controlled univariate analysis demonstrated 
that ursodeoxycholic acid use and CF-related diabetes or impaired glucose tolerance were 
associated with a higher frequency of an abnormal US, and that early Pseudomonas 
infection (<2 years of age) was associated with a higher frequency of normal US.
Our data show an association of abnormal US with ursodeoxycholic acid even after 
controlling for age. More subjects with an abnormal US were identified as having non-
cirrhotic liver disease in the CF registry a priori, likely secondary to documentation of 
elevated liver transaminases. As such, this association could be indicative of therapy for 
clinically suspected liver disease in the absence of detectable portal hypertension and not 
imply causality. Although high-dose ursodeoxycholic acid has been associated with 
increased morbidity, including mortality and cancer in adults with primary sclerosing 
cholangitis16,17, we are not aware of prior studies that suggest that ursodeoxycholic acid 
may induce US abnormalities in children with CF. Our data, however, neither confirm nor 
exclude this possibility and we believe this deserves further study.
Our finding of an association between CF-related diabetes or impaired glucose tolerance and 
an abnormal US that is independent of age is noteworthy. An association with CF-related 
diabetes and progressive liver disease has been previously reported18. Our data did not 
reveal any increased incidence of CF-related diabetes or impaired glucose tolerance in the 
homogeneous group. Thus, even though CF-related diabetes may be a marker of more 
severe CFTR dysfunction it may also be a marker of other insulin associated mechanisms, 
distinct from that of NAFLD, that impact liver disease.
Although this association could in part be related to the older age of the subjects and more 
frequent glycemic testing performed in this group, this trend remained after controlling for 
age. Most of the subjects tested for glucose metabolism were over 10 years of age, 
consistent with clinical guidelines19. Thus, even though this association should be regarded 
with caution as the number of subjects diagnosed with either CF-related diabetes or impaired 
glucose tolerance is small, there may be a higher overall prevalence of CF-related diabetes 
and impaired glucose tolerance than reported in this study.
Meconium ileus has historically been considered a risk factor for CF related liver disease 
(CFLD). However, a recent large, single-center analysis of 401 CF infants over a 25-year 
period and other studies have found no difference in the percentage of patients with 
meconium ileus who developed CFLD compared with those without liver disease 20-22. Our 
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results suggest that a history of meconium ileus increases risk for a homogeneous US 
pattern.
The significant association of early infection and colonization with Pseudomonas after 
controlling for age is the most provocative finding of this study. Many more subjects in the 
normal group were infected with Pseudomonas compared with the abnormal group. This 
may indicate a modifier gene(s) effect similar to the recent work by Li et al demonstrating 
an association between the meconium ileus modifier polymorphism SLC6A14 and early 
Pseudomonas infection23. This protective association could also be a marker of alteration in 
the gut or respiratory microbiome related to antibiotic exposure or reduction of systemic 
inflammation due to the early treatment of Pseudomonas infection. Changes in both the 
microbiome and systemic inflammation have been associated with NAFLD and other liver 
diseases 24,25. It could also mean that this set of patients may have a less vigorous immune 
response leading to early Pseudomonas colonization but decreased immune mediated liver 
inflammatory injury. This phenomenon may also be secondary to early identification of 
Pseudomonas infection leading to closer follow up or other unrecognized intervention that 
leads to a protective effect.
Other imaging technologies, notably transient elastography, which measures liver stiffness, 
has been shown to correlate with advanced fibrosis in pediatric liver diseases, including 
CFLD 26-28 but its utility in early fibrosis is unproven.
Our findings demonstrate that the frequency of heterogeneous US abnormalities is higher 
than previously described, with 3% having unanticipated sonographic cirrhosis. The 
association between CF-related diabetes and impaired glucose tolerance with abnormal US 
patterns and the protective effect of early Pseudomonas infection suggest potential 
mechanisms predisposing to liver disease that merit further study. Although the ultrasound 
grading system for this study is rigorous, it is descriptive and may not directly correlate with 
severity of liver disease in CF. We recognize that no histological correlation was available 
for the imaging patterns that are used in the grading system as liver biopsy was not part of 
this study. The findings in this study do not yet support routine monitoring with abdominal 
US, but ongoing clinical follow-up of this large study group will help define the utility of 
screening abdominal US and the clinical significance of the spectrum of findings in young 
children with CF as well as the potential role of US in tracking responses to newer therapies.
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Abbreviatons
CF cystic fibrosis
US ultrasound
FEV1% predicted forced expiratory volume in 1 second
NAFLD nonalcoholic fatty liver disease
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Figure. 
Violin plot of age distribution by ultrasound finding. NL=normal, HTG=heterogeneously 
increased echogenicity, HMG= homogeneously increased echogenicity, CIR=cirrhosis. 
Mean is demonstrated by the white dot and the 25th and 75th percentile by the lower and 
upper limits of the black bar. The width of the violin shows the relative proportion in each 
category based on age (y axis).
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